{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:12:45Z","timestamp":1784117565839,"version":"3.55.0"},"reference-count":45,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2026,7,3]]},"DOI":"10.1080\/14656566.2026.2691245","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:33:16Z","timestamp":1781764396000},"page":"865-874","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of zongertinib for the treatment of metastatic non-squamous non-small cell lung cancer with\n                    <i>HER2<\/i>\n                    TKD activating mutation"],"prefix":"10.1080","volume":"27","author":[{"given":"Miao","family":"Chen","sequence":"first","affiliation":[{"name":"The Second Affiliated Hospital of Zhejiang Chinese Medical University (Xinhua Hospital of Zhejiang Province)","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinal","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine","place":["Bronx, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyan","family":"Wu","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College of Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Cheng","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine","place":["Bronx, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108099"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01021-1"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00558-1"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13419"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102520"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.806737"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100260"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01361"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0306"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503704"},{"key":"e_1_3_5_13_1","unstructured":"Research C. For D.E. and FDA grants accelerated approval to zongertinib for non-squamous NSCLC with HER2 TKD activating mutations. FDA. 2025."},{"key":"e_1_3_5_14_1","unstructured":"Research C. For D.E. and FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung Cancer. FDA. 2026."},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/431525b"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c02302"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-3558"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-024-01751-w"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03100-5"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107992"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02245-z"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0007-9"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.07.129"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01323"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.02.011"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.12.126"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02420-5"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01727"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27052334"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2026.2623059"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511065"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-25-0605"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-3617"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113854"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2516969"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.1159"},{"key":"e_1_3_5_37_1","unstructured":"Boehringer ingelheim Beamion LUNG 2: a phase III open-label randomized active-controlled multi-centre trial evaluating orally administered zongertinib (BI 1810631) compared with standard of care as first-line treatment in patients with unresectable locally advanced or metastatic non-squamous non-small cell lung Cancer harbouring HER2 Tyrosine kinase domain Mutations. clinicaltrials.gov; 2026."},{"key":"e_1_3_5_38_1","unstructured":"Boehringer Ingelheim Beamion LUNG-3: a randomized controlled multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of Care in patients with early-stage resectable non-small cell lung Cancer (stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations. clinicaltrials.gov; 2026."},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1142087"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.70319"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1771869"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00720-9"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0547"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2191"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom9100629"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.70100"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt338"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2691245","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14656566.2026.2691245","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2691245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:37:47Z","timestamp":1784115467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2026.2691245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,7,3]]}},"alternative-id":["10.1080\/14656566.2026.2691245"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2026.2691245","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}